Wells Fargo
HCWB icon

Wells Fargo’s HCW Biologics HCWB Stock Holding History

Wells Fargo’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$360 Hold
167
– – ﹤0.01% 6422
2025
Q4 		$971 Sell
167
-116
-41% -$1.97K ﹤0.01% 6285
2025
Q3 		$6.29K Hold
283
– – ﹤0.01% 6033
2025
Q2 		$6.74K Buy
+283
New +$12.4K ﹤0.01% 6030
2024
Q2 		– Sell
-1
Closed -$247 – 7127
2024
Q1 		$247 Hold
1
– – ﹤0.01% 6446
2023
Q4 		$169 Hold
1
– – ﹤0.01% 6645
2023
Q3 		$249 Buy
+1
New +$495 ﹤0.01% 6531
2023
Q2 		– Hold
0
– – – 6673
2023
Q1 		– Hold
0
– – – 6865
2022
Q4 		– Hold
0
– – – 6640
2022
Q3 		– Hold
0
– – – 6920
2022
Q2 		– Hold
0
– – – 7066
2022
Q1 		– Hold
0
– – – 7350
2021
Q4 		– Hold
0
– – – 7453
2021
Q3 		– Hold
0
– – – 7184

Other funds holding HCWB

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo's HCWB Position: Q1 2026 in Review

Wells Fargo held its HCW Biologics (HCWB) position steady in Q1 2026 at 167 shares worth $360. The position accounts for ﹤0.01% of the portfolio, ranked #6422.

Wells Fargo first reported a position in HCWB in Q3 2023 and has held it in 7 quarters since. The position peaked at $6.74K in Q2 2025. 13 funds tracked by Wall St. Rank hold HCWB as of Q1 2026.

  • Wells Fargo held 167 shares of HCW Biologics worth $360 as of Q1 2026.
  • Wells Fargo left its HCW Biologics share count unchanged in Q1 2026.
  • HCW Biologics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6422 holding.
  • Wells Fargo first reported a position in HCW Biologics in Q3 2023 and has held it in 7 quarters since.
  • Wells Fargo's HCW Biologics position peaked at $6.74K in Q2 2025.
  • 13 funds tracked by Wall St. Rank held HCW Biologics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.